Northwire Canada EditionTuesday, July 21, 2026
Northwire
NVLH 0.075 −11.8% PHNM 0.345 +4.5% AEC 6.71 +11.5% IAU 1.90 +7.3% LOD 0.295 +0.0% FVL 0.990 +8.8% BAG 0.205 +20.6% FMN 0.240 +0.0% OMM 0.050 +0.0% VUL 0.430 +6.2% PNTR 0.330 +11.9% SWA 0.035 +0.0% GEN 0.065 +0.0% PAT 0.280 −21.1% TOM 0.115 +9.5% ALS 58.55 +2.9% NVLH 0.075 −11.8% PHNM 0.345 +4.5% AEC 6.71 +11.5% IAU 1.90 +7.3% LOD 0.295 +0.0% FVL 0.990 +8.8% BAG 0.205 +20.6% FMN 0.240 +0.0% OMM 0.050 +0.0% VUL 0.430 +6.2% PNTR 0.330 +11.9% SWA 0.035 +0.0% GEN 0.065 +0.0% PAT 0.280 −21.1% TOM 0.115 +9.5% ALS 58.55 +2.9%
M&A / Property

Telescope Innovations to Deliver First Self-Driving Lab for Korea's Largest Biopharma Manufacturers Association

TELI · Price

Executive Summary

  • Telescope Innovations announced that Korea’s largest biopharma association (KPBMA) has purchased and will install one of its Self‑Driving Lab (SDL) platforms at a new R&D facility in Seoul.
  • The SDL deployment marks the first AI‑driven training hub for drug discovery in Korea and establishes a strategic partnership aimed at broader SDL adoption across Korean pharma and other industries.
  • Telescope positions the deal as a gateway to accelerated pharmaceutical R&D in Asia and anticipates further regional deployments in agriculture, minerals, energy, and chemicals.

Key Details

  • Customer: Korean Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA).
  • Product: One Self‑Driving Lab (SDL) platform – an automated system integrating robotics, inline analytics, and AI/machine‑learning for continuous closed‑loop experimentation.
  • Installation Timeline: Installation to occur “in a matter of weeks” with commissioning shortly thereafter.
  • Strategic Purpose: SDL will serve as the core of KPBMA’s Convergence AI Institute for Drug Discovery (CAIID) training hub, providing education, up‑skilling, and demonstration of automated R&D capabilities.
  • Geographic Significance: First SDL deployment in South Korea; intended to catalyze broader adoption across Asian biopharma institutes and commercial labs.
  • Commercial Outlook: Telescope highlights expanding relevance of SDLs beyond pharma into agriculture, minerals, energy, and chemicals, citing the platform’s suitability for remote or high‑risk environments.
  • Leadership Comments:
  • Junhee Pyo (CAIID Vice Chief) – emphasizes innovation impact on Korean drug development.
  • Jason Hein (CTO, Telescope) – notes milestone for intelligent automation technology.
  • Henry Dubina (CEO, Telescope) – stresses Asia’s rapid market growth for lab automation and the partnership’s role in regional expansion.

Notable Quotes

  • “We anticipate that this Self‑Driving Lab will bring significant innovation to new drug development processes in Korea.” – Junhee Pyo, CAIID Vice Chief
  • “Delivering our first Self‑Driving Lab in South Korea will mark a major milestone for Telescope's intelligent automation technology…” – Jason Hein, CTO, Telescope Innovations
  • “Partnering with KPBMA on Korea's first AI‑driven SDL hub positions Telescope at the center of this momentum.” – Henry Dubina, CEO, Telescope Innovations
Read the original news release →

More from Telescope Innovations Corp.